Craft
4SC

4SC

Revenue

€14 M

FY, 2021

Market Capitalization

€17.7 M

2022-11-21

4SC Summary

Company summary

Overview
4SC is a biopharmaceutical company developing small-molecule drugs that target key indications in cancer with unmet medical needs. Its current product pipeline includes two programs in clinical development: resminostat, an orally administered histone deacetylase (HDAC) inhibitor with a mechanism of action that represents a therapy for a spectrum of oncology indications, both in monotherapy and in combination with other anti-cancer drugs); and domatinostat, an orally administered histone deacetylase (HDAC) inhibitor with a mode of action that was designed to strengthen the body’s own anti-tumor immune response.
Type
Public
Status
Active
Founded
1997
HQ
Planegg, DE | view all locations
Website
https://www.4sc.de/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Jason Loveridge

    Jason Loveridge, Chief Executive Officer (CEO) Chairman of the Management Board

  • Susanne Danhauser-Riedl

    Susanne Danhauser-Riedl, Chief Medical Officer (CMO)

LocationsView all

1 location detected

  • Planegg, BY HQ

    Germany

    Fraunhoferstraße 22

4SC Financials

Summary financials

Revenue (H1, 2022)
€175.0K
Gross profit (H1, 2022)
€50.0K
Net income (H1, 2022)
(€11.3M)
Cash (H1, 2022)
€15.8M
EBIT (H1, 2022)
(€8.5M)
Enterprise value
$1.9M

Footer menu